Notice: Function amp_is_available was called incorrectly. `amp_is_available()` (or `amp_is_request()`, formerly `is_amp_endpoint()`) was called too early and so it will not work properly. WordPress is currently doing the `init` hook. Calling this function before the `wp` action means it will not have access to `WP_Query` and the queried object to determine if it is an AMP response, thus neither the `amp_skip_post()` filter nor the AMP enabled toggle will be considered. It appears the plugin with slug `jetpack` is responsible; please contact the author. Please see Debugging in WordPress for more information. (This message was added in version 2.0.0.) in /var/www/wp-includes/functions.php on line 5835
Health Technology – Page 3 – Force Pharma Capital
Skip to content
Force Pharma Capital
Force Pharma Capital
Life Science Consulting, Business Development and Recruiting/Staffing
  • Home
  • About Us
  • Services
  • Pharmaceutical Blog
    • RLD
    • Excipients
    • Equipment
    • Health Technology
    • Regulatory Fees
  • Contact Us
  • FAQ
  • Portfolio

Category: Health Technology

Mayo researchers demonstrate senescent cell burden is reduced in humans by senolytic drugs – Mayo Clinic News Network

September 19, 2019 Blogger

Mayo researchers demonstrate senescent cell burden is reduced in humans by senolytic drugs — Read on newsnetwork.mayoclinic.org/discussion/mayo-researchers-demonstrate-senescent-cell-burden-is-reduced-in-humans-by-senolytic-drugs/

Continue Reading →

Posted in: Health Technology Filed under: FDA, fixed dose combination, pdufa

Study quantifies impact of NIH-sponsored trials on clinical cancer care | National Institutes of Health (NIH)

September 18, 2019 Blogger

Researchers found trials add value regardless of whether findings were positive or negative. — Read on www.nih.gov/news-events/news-releases/study-quantifies-impact-nih-sponsored-trials-clinical-cancer-care Great Article!

Continue Reading →

Posted in: Health Technology Filed under: FDA

FDA takes first action under new international collaboration with Australia and Canada designed to provide a framework for concurrent review of cancer therapies, approving treatment for patients with endometrial carcinoma | FDA

September 17, 2019 Blogger

Project Orbis provides a framework for concurrent submission and review of oncology drugs among its international partners. Under this project,…

Continue Reading →

Posted in: Health Technology Filed under: approvals, pdufa, technology

Statement alerting patients and health care professionals of NDMA found in samples of ranitidine | FDA

September 14, 2019 Blogger

The U.S. Food and Drug Administration has learned that some ranitidine medicines, including some products commonly known as the brand-name…

Continue Reading →

Posted in: Health Technology, Uncategorized Filed under: FDA

Drug Trials Snapshots: WAKIX | FDA

September 12, 2019 Blogger

Drug Trials Snapshots: WAKIX — Read on www.fda.gov/drugs/resources-information-approved-drugs/drug-trials-snapshots-wakix Wonder if this is a classified as a controlled substance.

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, pdufa

Drug Trials Snapshots: RINVOQ | FDA

Blogger

Drug Trial Snapshot — Read on www.fda.gov/drugs/resources-information-approved-drugs/drug-trials-snapshots-rinvoq Another inhibitor approved for oncology….

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, technology

Two-Pronged Approach Shows Promise as Effective Treatment Option in AML

Blogger

A new study identified pathways that may serve as therapeutic targets for overcoming drug resistance in acute myeloid leukemia. —…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, pdufa

Drug Trials Snapshots: ROZLYTREK | FDA

Blogger

ROZLYTREK is a drug used to treat adult patients with a type of non-small cell lung cancer (NSCLC) which is…

Continue Reading →

Posted in: Health Technology Filed under: approvals, FDA, pdufa

Ilixadencel/Sunitinib Combo Therapy Achieves Positive Results in Metastatic Renal Cell Cancer

September 9, 2019 Blogger

Results from a phase 2 study demonstrated complete tumor responses in patients with metastatic renal cell carcinoma treated with the…

Continue Reading →

Posted in: Health Technology Filed under: fixed dose combination, puffs

New Study Links Type 2 Diabetes Drug with Reduced Risk of Heart Failure

Blogger

New Study Links Type 2 Diabetes Drug with Reduced Risk of Heart Failure — Read on www.pharmacytimes.com/

Continue Reading →

Posted in: Health Technology Filed under: pdufa

Post navigation

Page 3 of 4
← Previous 1 2 3 4 Next →

Recent Posts

  • Most Recent Changes to the IID Database | FDA
  • The History, Benefits of Pharmaceutical REMS Programs
  • FDA approves first drug for treatment of peanut allergy for children

Recent Comments

  • flower bouquet delivery online on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma
  • cheap flowers online same day delivery on Trending News Today: Investigational Long-Acting HIV Injection Shows Efficacy in Study
  • flower arrangements for baby shower girl on FDA Grants Priority Review to Zanubrutinib for Relapsed/Refractory Mantle Cell Lymphoma

Archives

  • August 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • November 2018

Follow Us

Contact Us

  • Email
    forcepharma@icloud.com
  • Phone
    732-702-1824
  • Address
    265 Route 34 Lower Level, Colts Neck, New Jersey, 07722
Copyright © 2018 Force Pharma Capital